Abstract: A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.

Abstract: Provided is a valproic acid derivative for improving disadvantages or defects accompanying when valproic acid itself or the like is used as a medicine. Provided is a block copolymer which is a polymerized product of valproic acid and comprises a poly(ethylene glycol) segment and a poly(vinyl valproate) segment.

Abstract: A copolymer which includes hydrophilic and hydrophobic blocks, which can form nanoparticles in which a physiologically active substance can be efficiently packaged therein and which are stable under acidic conditions. The hydrophilic segment of the copolymer is composed of polyethylene glycol (PEG) and the hydrophobic segment is composed of polystyrene. The hydrophobic segment has a side chain, and the side chain has ends to which a cyclic nitroxide radical having a radical scavenging function and a trialkoxysilane are covalently bonded.

Abstract: An objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor, which has high bioavailability, low toxicity, and high therapeutic effectiveness, even when provided by oral administration. Another objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor which is effective in preventing or treating hepatic disorders. In order to achieve the above objectives, an acyl group is introduced into the primary amino group in the side chain of an ornithine unit in the poly(ornithine) segment of poly(ethylene glycol)-b-poly(ornithine), which spontaneously forms polymer micelles without polyion complex formation.

Abstract: [Object] To provide a derivative of a short chain fatty acid that can exhibit physiological functions inherent in the short chain fatty acid. [Solution] Provided is a block or graft copolymer including a hydrophobic segment of a repeat unit containing a short chain fatty acid ester that is hydrolyzable by esterase in vivo and a hydrophilic segment including a poly(ethylene glycol) chain. These copolymers are effective in the treatment or therapeutic treatment of various diseases or disorders, including cancer.

Abstract: Incorporation of L-DOPA into a carrier in a form of a block copolymer (PEG-b-poly(3,4-hydroxy-protected L-DOPA)) significantly improves the retention of the agent in the blood, thus mitigating a shortcoming associated with L-DOPA in treating Parkinson's disease.

Abstract: A copolymer which includes hydrophilic and hydrophobic blocks, which can form nanoparticles in which a physiologically active substance can be efficiently packaged therein and which are stable under acidic conditions. The hydrophilic segment of the copolymer is composed of polyethylene glycol (PEG) and the hydrophobic segment is composed of polystyrene. The hydrophobic segment has a side chain, and the side chain has ends to which a cyclic nitroxide radical having a radical scavenging function and a trialkoxysilane are covalently bonded.

Abstract: Provided is a coating agent which can be stably immobilized on metal surface, and which can give blood compatibility. Provided is a copolymer which is usable as the above-mentioned coating agent that comprises PEG segment and a segment which has a phosphoric acid residue (PO(—OH)2) and a cyclic nitroxideradical randomly as a side chain or a pendant group.

Abstract: A method for efficiently producing a poly(ethylene glycol)-b-poly(halomethylstyrene), a novel poly(ethylene glycol)-b-poly(halomethylstyrene) produced using the method, and a derivative thereof. The target novel copolymer can be provided by introducing a functional group, which enables reversible addition-fragmentation chain transfer (RAFT) polymerization, to the ? terminal of poly(ethylene glycol) and copolymerizing the resulting poly(ethylene glycol) with a halomethylstyrene.

Abstract: An object of the present invention is to provide a composition that serves as an efficient arginine substrate for inducible NO synthase (iNOS) in tumor. The present invention provides a polyion complex (PIC) of PEG-b-poly(L-Arg) or poly(L-Arg)-b-PEG-b-poly(L-Arg) and a polyanionic polymer, and use thereof.

Abstract: Provided is a coating agent which can be stably immobilized on metal surface, and which can give blood compatibility. Provided is a copolymer which is usable as the above-mentioned coating agent that comprises PEG segment and a segment which has a phosphoric acid residue (PO(—OH)2) and a cyclic nitroxideradical randomly as a side chain or a pendant group.

Abstract: [Problem] To provide a composition capable of effectively preventing adhesion. [Solution] An adhesion-preventing preparation comprising, as an active ingredient, a composition comprising an A-B-A triblock copolymer, in which A denotes a cationically chargeable polymer block and B denotes a water-soluble block that comprises a poly(ethylene glycol) (or poly(oxyethylene)) chain, and a polyanionic polymer.

Abstract: An object of the present invention is to provide a composition that serves as an efficient arginine substrate for inducible NO synthase (iNOS) in tumor. The present invention provides a polyion complex (PIC) of PEG-b-poly(L-Arg) or poly(L-Arg)-b-PEG-b-poly(L-Arg) and a polyanionic polymer, and use thereof.

Abstract: [Problem] To provide a physiologically active peptide-loaded stable composition for injection into living bodies. [Solution] A composition containing a triblock copolymer represented by formula (I), a polyanionic polymer and a physiologically active peptide: CNR-PEG-CNR??(I) in the formula, CNR moieties are each independently a polymer segment containing a repeating unit that contains, as a part of a pendant group, a cyclic nitroxide radical bonded to a main polymer chain via a linking group that contains at least one amino group, and PEG is a segment that contains poly(ethylene glycol).

Abstract: A substrate surface on which either a substance to detect analyte or an analyte per se is immobilized, which surface is formed by a treatment of substrate surface with a liquid which contains uncrosslinked polymer based on polyethylene glycol chain segment, said treatment conducted either simultaneously with the immobilization of said substance or analyte or after said substance or analyte has been immobilized on said surface. The non-specific adsorption of impurity protein or the like which is co-existent in sample for assay is significantly restrained.

Abstract: Provided is a triblock copolymer represented by General Formula (I): CNR-PEG-CNR??(1) or a polycation thereof, wherein each CNR is independently a polymer segment having a repeating unit containing as part of a pendant group a cyclic nitroxide radical that binds to the polymer main chain via a linking group having at least one imino group or ether bond, and PEG is a segment containing poly(ethylene glycol).

Abstract: [Problem] To provide a method for efficiently producing a poly(ethylene glycol)-b-poly(halomethylstyrene), a novel poly(ethylene glycol)-b-poly(halomethylstyrene) produced using the method, and a derivative thereof. [Solution] The target novel copolymer can be provided by introducing a functional group, which enables reversible addition-fragmentation chain transfer (RAFT) polymerization, to the ? terminal of poly(ethylene glycol) and copolymerizing the resulting poly(ethylene glycol) with a halomethylstyrene.

Abstract: Provided is a prodrug of 2-nitro-1-imidazolepropionic acid and a therapeutically active organic compound having on the molecule an amino group, a cyclic amino group or a hydroxyl group, particularly a prodrug in which the therapeutically active organic compound is selected from among antitumor agents. The prodrug cleaves specifically under hypoxic conditions in vivo to exhibit the inherent therapeutic activity.

Abstract: [Problem] To provide a composition capable of effectively preventing adhesion. [Solution] An adhesion-preventing preparation comprising, as an active ingredient, a composition comprising an A-B-A triblock copolymer, in which A denotes a cationically chargeable polymer block and B denotes a water-soluble block that comprises a poly(ethylene glycol) (or poly(oxyethylene)) chain, and a polyanionic polymer.

Abstract: [Problem] To provide a physiologically active peptide-loaded stable composition for injection into living bodies. [Solution] A composition containing a triblock copolymer represented by formula (I), a polyanionic polymer and a physiologically active peptide: CNR-PEG-CNR??(I) in the formula, CNR moieties are each independently a polymer segment containing a repeating unit that contains, as a part of a pendant group, a cyclic nitroxide radical bonded to a main polymer chain via a linking group that contains at least one amino group, and PEG is a segment that contains poly(ethylene glycol).